Go to main content

GC Pharma


Rooting for Scientific Advancements and Dreams for a Brighter Future

Mogam Science Scholarship Foundation

The Mogam Science Scholarship Foundation was created with the goal of encouraging and supporting young Korean scientists with scholarships and research grants to enable them to contribute to scientific and technological advancements in and outside Korea.


  • Establishment dateDecember 2005
  • Founding purposeTo contribute to scientific and technological advancements as well as national progress through active recruitment of young Korean scientists and supporting them with scholarships and research grants.

Scholar Selection Process

  • EligibilityStudents confirmed to have entered master’s, doctoral, or combined master-doctoral degree courses
  • Areas of application1) Biology and other areas of biosciences
    2) Medicine and pharmacology
  • Selection criteria1) Area of research interest
    2) Financial status (whether benefitting from other scholarships, receiving help from family members, etc.)
    3) Personal statement

Screening Process

  1. Document-based review

  2. Interview

  3. Final decision announced

※ Visit the Mogam Science Scholarship Foundation website for more information.

Korea Hemophilia Foundation (KHF)

The late founding chairman of GC Pharma, Huh Young-sup, founded the KHF in line with the company’s commitment to producing hemophilia treatments, beginning in 1974, under its mission of serving Korean society, local communities, and fellow Koreans. The foundation provides a wide range of support to facilitate systematic and efficient treatment and rehabilitation for persons struggling with hereditary hemophilia.


GC Pharma, which began producing plasma derivatives in the early 1970s, turned its attention to production of its own hemophilia treatment (an anti-hemophilic factor or AHF) in 1974. The company’s determination to help hemophilic patients culminated with creation of the KHF two decades later. GC Pharma consulted hemophilia organizations in the United States and other developed countries, and sent a delegation to a hemophilia treatment center in Bonn, Germany, to survey its facilities and management. The company then teamed up with the mothers of hemophilic patients and the Hemophilic Patients Rehabilitation Association to launch the KHF.


  • Medical centersWith the aim of enhancing hemophilic patient access to quality medical care, GC Pharma transformed its headquarters, then at Yongdu-dong in Seoul, into Seoul Hospital. Upon request from hemophilic patients elsewhere in Korea, the company opened Gwangju Hospital in 2006 and Busan Hospital in 2007, providing quality care and convenience for hemophilic patients nationwide.
  • Summer campsGC Pharma also organizes summer camps for hemophilic patients each year, lasting three days each. Participating patients, given their medical needs, are teamed up with doctors, nurses and physiotherapists. The camps are a great opportunity for patients to meet fellow patients and share their experiences and interests.
  • Rehabilitation medicineWith help from Prof. Yu Myeong-cheol, an orthopedist, and his team of trainees and researchers at College of Medicine, Kyung Hee University, GC Pharma has introduced joint surgery and rehabilitation medicine programs for hemophilic patients. The company continues to provide free tests necessary for these programs, including anti-coagulation factor, human immunodeficiency virus, liver, and general blood tests. The company also provides von Willebrand factor tests to identify vWD patients, while the carrier tests the company provides also help identify individuals carrying genetic factors and prevent the onset of the disease in them.
  • Medical financingGC Pharma provides financial assistance for the medical costs of hemophilic patients through a variety of programs. In particular, the company introduced the At-Home Care Team in 2005 to identify and support hemophilic patients struggling with poverty and physical disabilities.